Amgen takes a swing at regenerative immunology with $721M acquisition of Rodeo Therapeutics
With blockbuster immunology meds Enbrel and Otezla already in the fold, Amgen has mostly stood pat on infusing new blood into its legacy pipeline. But that success won’t last forever, and Amgen is taking a far-looking bet on a private biotech forging a new pathway to treat immune system diseases.
Amgen will pay $55 million upfront and a devilish $666 million in future milestones to acquire Seattle-based Rodeo Therapeutics and its small-molecule therapies targeting the 15-prostaglandin dehydrogenase (15-PGDH) enzyme potentially implicated in a range of indications, the companies said Tuesday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,600+ biopharma pros reading Endpoints daily — and it's free.